Telix Pharmaceuticals & DKFZ partner for image-guided prostate surgery
Category: #health  By Paroma Bhattacharya  Date: 2019-08-05
  • share
  • Twitter
  • Facebook
  • LinkedIn

Telix Pharmaceuticals & DKFZ partner for image-guided prostate surgery

· Telix would work with DKFZ for required translational research to evaluate technology in surgical settings.

· Agreement has a negotiated and exclusive option to license the new technology for commercial-level development.

Telix Pharmaceuticals Limited, (Telix), an Australian biopharmaceutical company aimed at the development of therapeutic and diagnostic products based upon molecularly-targeted radiation (MTR) or targeted radiopharmaceuticals, has reportedly announced a new collaboration with German Cancer Research Center (DKFZ) for prostate cancer through image-guided surgery.

Under this collaboration, Telix would work with DKFZ and associated researchers to carry out required translational research studies to assess the technology in surgical settings.

CEO of Telix Group, Dr. Christian Behrenbruch stated that the amazing research of the scientists at DKFZ & Heidelberg has a lot of potential in developing the efficiency and quality of utilizing image-guided techniques for conducting robotic surgery. Previously, Telix has aimed at use of PSMA imaging in post-prostatectomy biochemical renewal settings. Dr. Christian added that this partnership would explore how Image-Guided surgery and PET could be used to enhance results from prostatectomy, further extending the impact of molecular imaging while handling prostate cancer.

Heidelberg University Clinic and DKFZ researchers created a next-generation radiotracer made on the basis of 68Ga-PSMA-11 that contains a fluorophore along with the capability to molecularly target radiation for imaging with Positron Emission Tomography (PET). The outcome is a technology that can concurrently image PET with prostate cancer and facilitate guidance for intra-operative surgical development through fluorescence imaging.

Dr. Ann-Christin Baranski, principal investigator at DKFZ and scientist at German Cancer Consortium and Nuclear Medicine department at University Hospital of Freiburg stated that researchers at Telix have made immense progress in the commercialization of PSMA-11 PET imaging, which was a technology initially developed at DKFZ . The company believes that Telix is a ideal commercial partner for this new technology and looks forward to work with Telix to understand the impact of the technology on patients in future.

The collaboration agreement has a negotiated and exclusive option to license the new technology for commercial-level development.

Source Credits: https://www.globenewswire.com/news-release/2019/08/05/1896616/0/en/Telix-Pharmaceuticals-and-German-Cancer-Research-Center-DKFZ-Enter-into-Collaboration-and-Option-Agreement-for-Image-Guided-Prostate-Surgery.html



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Exicure reveals positive data from XCUR17 clinical trial for Psoriasis
Exicure reveals positive data from XCUR17 clinical trial for Psoriasis
By Paroma Bhattacharya

Clinical trials play a vital role in developing new treatments that could immensely improve a person’s living. Today, researchers and pharmaceutical company are working hard for making breakthroughs in psoriasis ...

Principia Biopharma reveals data from Phase 1/2 trial targeting ITP
Principia Biopharma reveals data from Phase 1/2 trial targeting ITP
By Paroma Bhattacharya

Immune thrombocytopenia (ITP) is a type of blood abnormality that creates a shortage of blood cell fragments known as platelets required for normal blood clotting. While children with ITP get cured without treatme...

Indian social commerce startup Mall91 raises $7.5M in Series A round
Indian social commerce startup Mall91 raises $7.5M in Series A round
By Paroma Bhattacharya

  • Mall91 reportedly plans on using the acquired funds for product development, boosting hiring and driving supply chain efforts, and realizing its global expansion ambitions.